After two decades of scientifically and medically proven success in their field, Lightlake Therapeutics' experts have been granted ethical approval to begin selecting and gene testing subjects for a trial of a simple, safe and effective treatment for what the World Health Organisation has described as a global epidemic of unhealthy eating and obesity.
A Phase II trial for the everyday treatment against obesity and the overeating of unhealthy food, by nasal spray and a behavioural programme, will aim to prove that Lightlake's treatment can break the addictive habit of unhealthy eating, significantly reduce weight, and train the mind to embark on a healthier dietary lifestyle and sustained weight-loss.
Obesity is an epidemic that is resulting in millions of preventable deaths worldwide. The American Cancer Society estimates that over 100,000 Americans are dying from obesity and over eating related cancers every year and the estimated healthcare cost alone is $147 billion every year.
By 2012, it's expected that more than two billion people will be overweight and 600 million will be obese. The U.S. Center for Disease Control and Prevention and Department of Health in the UK both estimate that 60% of men and 50% of women and 25% of children will be obese by 2050 if current trends continue.
Lightlake has been given ethical approval to begin subject selection for Phase II clinical trial under the direction of its trial coordinator Professor Hannu Eero Rafael Alho, Professor of Addiction Medicine, University of Helsinki. The Trial is being conducted in conjunction with the National Institute for Health and Welfare, in Helsinki. It will last 6 months and results are expected in the fall of 2010.
Lightlake is pioneering the treatment of one of the world's biggest killers and will be initially focused on addressing one form of obesity - Binge Eating Disorder (BED) - that effects one in three obese people. To date existing interventions from diets to drugs and surgery have failed to deliver a sustainable solution to the obesity epidemic that is resulting in the global healthcare crisis. Those products currently on the market have questions of efficacy and may come with undesirable side effects. This trial marks a new departure in the treatment of obesity.
Lightlake Therapeutics is an international team of research scientists, pharmacologists and doctors backed by investors, who are pioneering the search for a safe, effective and simple treatment for the epidemic of obesity and unhealthy eating. Its expertise is derived from an existing treatment that has recorded a 78% success rate in treating the over consumption of alcohol.
Dr. David Sinclair, Ph.D., Lightlake's Chief Science Officer says: